Invention Grant
US09226966B2 Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents
有权
用于预防用包含蒽环类化疗药物的ERBB2靶向免疫脂质体治疗心脏毒性的剂量和给药
- Patent Title: Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents
- Patent Title (中): 用于预防用包含蒽环类化疗药物的ERBB2靶向免疫脂质体治疗心脏毒性的剂量和给药
-
Application No.: US13912167Application Date: 2013-06-06
-
Publication No.: US09226966B2Publication Date: 2016-01-05
- Inventor: Joseph G. Reynolds , Kenneth J. Olivier, Jr. , Bart S. Hendriks , Thomas Wickham , Stephan Klinz , Elena Geretti
- Applicant: Merrimack Pharmaceuticals, Inc.
- Applicant Address: US MA Cambridge
- Assignee: MERRIMACK PHARMACEUTICALS, INC.
- Current Assignee: MERRIMACK PHARMACEUTICALS, INC.
- Current Assignee Address: US MA Cambridge
- Agency: Honigman Miller Schwartz and Cohn LLP
- Agent Cynthia M. Bott; Jonathan P. O'Brien
- Main IPC: G01N33/566
- IPC: G01N33/566 ; A61K47/42 ; A61K31/7042 ; A61K47/48 ; A61K31/704
Abstract:
Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
Public/Granted literature
Information query
IPC分类:
